Cyron Therapeutics has successfully developed a next-generation self-amplifying mRNA (saRNA) vaccine platform technology. This technology allows mRNA to self-amplify in the body, achieving the same efficacy with just one-tenth the dose of conventional mRNA vaccines.
The saRNA platform can be applied to various fields including infectious disease vaccines, cancer vaccines, and rare disease treatments. The significant reduction in production costs is expected to dramatically improve vaccine accessibility in developing countries.
Preclinical trial results showed that saRNA-based flu vaccines induced stronger and more sustained immune responses compared to conventional vaccines, with reduced side effects. The company aims to enter Phase 1 clinical trials early next year.
With this technology development, Cyron Therapeutics becomes the third company globally to possess self-amplifying mRNA technology after Moderna and BioNTech, with patent applications already completed.